DIANTHUS THERAPEUTICS INC (DNTH) competitors & alternatives
Health Care · NASDAQ
DIANTHUS THERAPEUTICS INC (DNTH)'s top competitors and alternatives — its most similar public companies — include ARCUS BIOSCIENCES INC (RCUS), CELLDEX THERAPEUTICS INC (CLDX), Cue Biopharma, Inc. (CUE), JADE BIOSCIENCES INC (JBIO), AVALO THERAPEUTICS INC (AVTX), ELEDON PHARMACEUTICALS INC (ELDN), FORTE BIOSCIENCES INC (FBRX), KYVERNA THERAPEUTICS INC (KYTX), Immunic, Inc. (IMUX), JANUX THERAPEUTICS INC (JANX), CRISPR THERAPEUTICS AG (CRSP) and AbbVie (ABBV). These are DIANTHUS THERAPEUTICS INC's closest public-company peers by sub-industry, sector and business themes and is informational only — not financial advice.
Top DNTH competitors & alternatives
-
ARCUS BIOSCIENCES INCRCUSHealth Care
A clinical-stage biotech developing first-in-class and best-in-class small molecules and antibodies for cancer immunotherapy, with lead HIF-2α inhibitor in…
$29.97 (as of 2026-07-22) · market cap $3.7B
-
CELLDEX THERAPEUTICS INCCLDXHealth Care
A clinical-stage biopharmaceutical company developing mast cell-targeted monoclonal and bispecific antibodies for chronic urticaria, inflammatory skin…
$34.77 (as of 2026-07-22) · market cap $2.7B
-
Cue Biopharma, Inc.CUEHealth Care
Cue Biopharma engineers injectable biologics that selectively modulate disease-specific T cells to restore immune tolerance in autoimmune diseases and activate…
$34.20 (as of 2026-07-22) · market cap $144M
-
JADE BIOSCIENCES INCJBIOHealth Care
Jade Biosciences is a clinical-stage biotech developing next-generation monoclonal antibodies with extended half-lives to treat autoimmune diseases like IgA…
$19.85 (as of 2026-07-22) · market cap $1.2B
-
AVALO THERAPEUTICS INCAVTXHealth Care
Clinical-stage biotech developing abdakibart, a humanized anti-IL-1β antibody for hidradenitis suppurativa with Phase 2 data readout expected mid-2026.
$18.15 (as of 2026-07-22) · market cap $961M
-
ELEDON PHARMACEUTICALS INCELDNHealth Care
Eledon Pharmaceuticals is a clinical-stage biotech developing immune-modulating therapies for autoimmune diseases and organ transplantation.
$3.72 (as of 2026-07-22) · market cap $287M
-
FORTE BIOSCIENCES INCFBRXHealth Care
A clinical-stage biotech developing an anti-CD122 antibody (FB102) to modulate immune cells in autoimmune diseases, with promising early celiac disease data…
$56.63 (as of 2026-07-22) · market cap $1.2B
-
KYVERNA THERAPEUTICS INCKYTXHealth Care
Kyverna is a clinical-stage immunology biotech developing novel investigational therapeutics with no approved products and complete dependence on successful…
$7.40 (as of 2026-07-22) · market cap $452M
-
Immunic, Inc.IMUXHealth Care
Immunic is a late-stage biotech developing oral small-molecule therapies for multiple sclerosis and gastrointestinal diseases with Phase 3 data expected in…
$15.11 (as of 2026-07-22) · market cap $206M
-
JANUX THERAPEUTICS INCJANXHealth Care
Janux Therapeutics is a clinical-stage biotech developing next-generation, tumor-activated bispecific immunotherapies to improve the safety and efficacy of…
$15.62 (as of 2026-07-22) · market cap $953M
-
CRISPR THERAPEUTICS AGCRSPHealth Care
CRISPR Therapeutics develops gene-editing medicines using CRISPR/Cas9 technology, with the first approved CRISPR therapy (CASGEVY) for sickle cell disease and…
$47.24 (as of 2026-07-22) · market cap $4.6B
-
AbbVieABBVHealth Care
Global biopharmaceutical company with leadership positions in immunology, neuroscience, oncology, and aesthetics targeting complex diseases.
$253.30 (as of 2026-07-22) · market cap $452.5B
Not quite? Describe exactly what you want →
Peers are DIANTHUS THERAPEUTICS INC's closest public companies by shared sub-industry, sector and business themes. See the full profile: DIANTHUS THERAPEUTICS INC (DNTH).
Last updated 2026-07-22.
Informational only — NOT financial advice. Company data is sourced from SEC EDGAR + Finnhub and shown with its as-of date.